KR20060009846A - Ｐｐａｒ 조절자로서의 알파 치환된 카복실산 - Google Patents
Ｐｐａｒ 조절자로서의 알파 치환된 카복실산 Download PDFInfo
- Publication number
- KR20060009846A KR20060009846A KR1020057019591A KR20057019591A KR20060009846A KR 20060009846 A KR20060009846 A KR 20060009846A KR 1020057019591 A KR1020057019591 A KR 1020057019591A KR 20057019591 A KR20057019591 A KR 20057019591A KR 20060009846 A KR20060009846 A KR 20060009846A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- phenyl
- oxazol
- ethoxy
- formula
- Prior art date
Links
- 0 *c(cc1)ccc1C1=NC=C=C1 Chemical compound *c(cc1)ccc1C1=NC=C=C1 0.000 description 8
- AUSUPLOVHHBOEY-UHFFFAOYSA-O CC(C)(C(O)=O)Oc1cccc(-c2cc(OCCC(CC3)CCN3C(N)=CC=C(C)[NH3+])ccc2)c1 Chemical compound CC(C)(C(O)=O)Oc1cccc(-c2cc(OCCC(CC3)CCN3C(N)=CC=C(C)[NH3+])ccc2)c1 AUSUPLOVHHBOEY-UHFFFAOYSA-O 0.000 description 1
- CDRIZXUWMMVWTQ-VQHVLOKHSA-N CCOC(C1(CCC1)Oc1ccc(/C=C/Cc2c(C)[o]c(-c3ccccc3)n2)cc1)=O Chemical compound CCOC(C1(CCC1)Oc1ccc(/C=C/Cc2c(C)[o]c(-c3ccccc3)n2)cc1)=O CDRIZXUWMMVWTQ-VQHVLOKHSA-N 0.000 description 1
- LICMWBWCSGKWNX-UHFFFAOYSA-N CCOC(C1(Cc(cc2)cnc2OCCc2c(C)[o]c(-c3ccccc3)n2)OCCC1)=O Chemical compound CCOC(C1(Cc(cc2)cnc2OCCc2c(C)[o]c(-c3ccccc3)n2)OCCC1)=O LICMWBWCSGKWNX-UHFFFAOYSA-N 0.000 description 1
- GQQLWKZRORYGHY-UHFFFAOYSA-N CCOC(C1OCCC1)=O Chemical compound CCOC(C1OCCC1)=O GQQLWKZRORYGHY-UHFFFAOYSA-N 0.000 description 1
- YGPBAGVCOGYWJI-UHFFFAOYSA-N CCOC(Cc(cn1)ccc1OCCc1c(C)[o]c(-c2ccccc2)n1)C(OCC)=O Chemical compound CCOC(Cc(cn1)ccc1OCCc1c(C)[o]c(-c2ccccc2)n1)C(OCC)=O YGPBAGVCOGYWJI-UHFFFAOYSA-N 0.000 description 1
- FGKGPWJVDRKQKT-UHFFFAOYSA-N COC(C1(CCOCC1)C(c(cc1)ccc1OCCC=C)O)=O Chemical compound COC(C1(CCOCC1)C(c(cc1)ccc1OCCC=C)O)=O FGKGPWJVDRKQKT-UHFFFAOYSA-N 0.000 description 1
- IPWZPTYWJHXUHD-UHFFFAOYSA-N Cc1c(CCOc2ccc(C=O)cc2)nc(-c2ccccc2)[o]1 Chemical compound Cc1c(CCOc2ccc(C=O)cc2)nc(-c2ccccc2)[o]1 IPWZPTYWJHXUHD-UHFFFAOYSA-N 0.000 description 1
- LNHMHVXNKZZZCI-UHFFFAOYSA-N Cc1c(CCOc2ccc(CC3(CCCCC3)C(O)=O)cc2)nc(-c2ccccc2)[o]1 Chemical compound Cc1c(CCOc2ccc(CC3(CCCCC3)C(O)=O)cc2)nc(-c2ccccc2)[o]1 LNHMHVXNKZZZCI-UHFFFAOYSA-N 0.000 description 1
- KLUDVNCBKDPJBN-UHFFFAOYSA-N Cc1c(CCOc2ccc(CI)cn2)nc(-c2ccccc2)[o]1 Chemical compound Cc1c(CCOc2ccc(CI)cn2)nc(-c2ccccc2)[o]1 KLUDVNCBKDPJBN-UHFFFAOYSA-N 0.000 description 1
- GXHAENUAJYZNOA-UHFFFAOYSA-N NC(C1OCCC1)=O Chemical compound NC(C1OCCC1)=O GXHAENUAJYZNOA-UHFFFAOYSA-N 0.000 description 1
- VQGHOUODWALEFC-UHFFFAOYSA-N c(cc1)ccc1-c1ncccc1 Chemical compound c(cc1)ccc1-c1ncccc1 VQGHOUODWALEFC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/14—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/30—Unsaturated compounds
- C07C62/34—Unsaturated compounds containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46321303P | 2003-04-15 | 2003-04-15 | |
| US60/463,213 | 2003-04-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060009846A true KR20060009846A (ko) | 2006-02-01 |
Family
ID=33300053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020057019591A KR20060009846A (ko) | 2003-04-15 | 2004-04-01 | Ｐｐａｒ 조절자로서의 알파 치환된 카복실산 |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1615899A1 (ja) |
| JP (1) | JP2006523671A (ja) |
| KR (1) | KR20060009846A (ja) |
| CN (1) | CN1805943A (ja) |
| AP (1) | AP2005003418A0 (ja) |
| AR (1) | AR044514A1 (ja) |
| AU (1) | AU2004230316A1 (ja) |
| BR (1) | BRPI0409429A (ja) |
| CA (1) | CA2521915A1 (ja) |
| CL (1) | CL2004000800A1 (ja) |
| EA (1) | EA200501462A1 (ja) |
| EC (1) | ECSP056105A (ja) |
| IS (1) | IS8033A (ja) |
| MA (1) | MA27764A1 (ja) |
| MX (1) | MXPA05010967A (ja) |
| NL (1) | NL1025946C2 (ja) |
| NO (1) | NO20055370L (ja) |
| OA (1) | OA13157A (ja) |
| PA (1) | PA8600201A1 (ja) |
| PE (1) | PE20050415A1 (ja) |
| TN (1) | TNSN05262A1 (ja) |
| TW (1) | TW200510353A (ja) |
| UY (1) | UY28266A1 (ja) |
| WO (1) | WO2004092145A1 (ja) |
| ZA (1) | ZA200508362B (ja) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008500357A (ja) * | 2004-05-25 | 2008-01-10 | メタボレックス インコーポレーティッド | Ｐｐａｒのモジュレーターとしての置換されたトリアゾールおよびこれらの調製方法 |
| CA2607617A1 (en) | 2005-05-09 | 2006-11-16 | Achillion Pharmaceuticals, Inc. | Thiazole compounds and methods of use |
| CN101553475B (zh) | 2006-10-30 | 2013-04-24 | 色品疗法有限公司 | 作为组蛋白脱乙酰基酶抑制剂的异羟肟酸 |
| PT2125711E (pt) * | 2007-03-08 | 2014-02-05 | Albireo Ab | Pirimidinas como inibidores de quinase |
| WO2008147557A2 (en) | 2007-05-22 | 2008-12-04 | Achillion Pharmaceuticals, Inc. | Heteroaryl substituted thiazoles and their use as antiviral agents |
| US8106209B2 (en) | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
| EP2303881A2 (en) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| US8134000B2 (en) | 2008-07-14 | 2012-03-13 | Gilead Sciences, Inc. | Imidazolyl pyrimidine inhibitor compounds |
| US8344018B2 (en) | 2008-07-14 | 2013-01-01 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
| KR20110038159A (ko) | 2008-07-28 | 2011-04-13 | 길리애드 사이언시즈, 인코포레이티드 | 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물 |
| JP2012529514A (ja) | 2009-06-08 | 2012-11-22 | ギリアード サイエンシーズ， インコーポレイテッド | シクロアルキルカルバメートベンズアミドアニリンｈｄａｃ阻害剤化合物 |
| US8258316B2 (en) | 2009-06-08 | 2012-09-04 | Gilead Sciences, Inc. | Alkanoylamino benzamide aniline HDAC inhibitor compounds |
| DE102010055499A1 (de) * | 2010-12-22 | 2011-06-16 | W.C. Heraeus Gmbh | Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon |
| ES2586213T3 (es) | 2011-10-31 | 2016-10-13 | Xenon Pharmaceuticals Inc. | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |
| CN104093716B (zh) | 2011-10-31 | 2017-06-23 | 克赛农制药股份有限公司 | 联芳醚磺酰胺化合物及其作为治疗剂的用途 |
| FR2982858B1 (fr) * | 2011-11-18 | 2013-11-29 | Rhodia Operations | Procede de fabrication de composes comprenant des fonctions nitriles |
| FR2984322B1 (fr) * | 2011-12-16 | 2013-12-20 | Rhodia Operations | Procede de fabrication de composes comprenant des fonctions nitriles |
| MX2014014234A (es) | 2012-05-22 | 2015-05-07 | Genentech Inc | Benzamidas n-sustituidas y su uso en el tratamiento del dolor. |
| CN104797555B (zh) | 2012-07-06 | 2017-12-22 | 基因泰克公司 | N‑取代的苯甲酰胺及其使用方法 |
| RU2015143906A (ru) | 2013-03-14 | 2017-04-18 | Дженентек, Инк. | Замещенные триазолопиридины и способы их применения |
| WO2014144545A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
| KR20160090846A (ko) | 2013-11-27 | 2016-08-01 | 제넨테크, 인크. | 치환된 벤즈아마이드 및 이의 이용 방법 |
| WO2016007534A1 (en) | 2014-07-07 | 2016-01-14 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| US10179767B2 (en) | 2015-05-22 | 2019-01-15 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| JP2018526371A (ja) | 2015-08-27 | 2018-09-13 | ジェネンテック， インコーポレイテッド | 治療化合物及びその使用方法 |
| CR20180242A (es) | 2015-09-28 | 2018-08-10 | Genentech Inc | Compuestos terapéuticos y sus métodos de uso |
| WO2017091592A1 (en) | 2015-11-25 | 2017-06-01 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| WO2017172802A1 (en) | 2016-03-30 | 2017-10-05 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| CR20190236A (es) | 2016-10-17 | 2019-09-09 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| EP3601273B1 (en) | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| TW202000651A (zh) | 2018-02-26 | 2020-01-01 | 美商建南德克公司 | 治療性組成物及其使用方法 |
| CN111936494A (zh) | 2018-03-30 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1088824E (pt) * | 1999-09-30 | 2004-04-30 | Pfizer Prod Inc | Pirrolil-amidas biciclicas como inibidores de glicogenio-fosforilase |
| WO2002064130A1 (en) * | 2001-02-15 | 2002-08-22 | Pfizer Products Inc. | Proliferative activator receptor (ppar) compounds |
-
2004
- 2004-04-01 EA EA200501462A patent/EA200501462A1/ru unknown
- 2004-04-01 EP EP04725121A patent/EP1615899A1/en not_active Withdrawn
- 2004-04-01 KR KR1020057019591A patent/KR20060009846A/ko not_active Application Discontinuation
- 2004-04-01 BR BRPI0409429-8A patent/BRPI0409429A/pt not_active IP Right Cessation
- 2004-04-01 CN CNA2004800167362A patent/CN1805943A/zh active Pending
- 2004-04-01 AU AU2004230316A patent/AU2004230316A1/en not_active Abandoned
- 2004-04-01 OA OA1200500283A patent/OA13157A/en unknown
- 2004-04-01 JP JP2006506478A patent/JP2006523671A/ja active Pending
- 2004-04-01 WO PCT/IB2004/001159 patent/WO2004092145A1/en not_active Application Discontinuation
- 2004-04-01 AP AP2005003418A patent/AP2005003418A0/xx unknown
- 2004-04-01 MX MXPA05010967A patent/MXPA05010967A/es not_active Application Discontinuation
- 2004-04-01 CA CA002521915A patent/CA2521915A1/en not_active Abandoned
- 2004-04-12 PE PE2004000361A patent/PE20050415A1/es not_active Application Discontinuation
- 2004-04-13 UY UY28266A patent/UY28266A1/es not_active Application Discontinuation
- 2004-04-13 AR ARP040101236A patent/AR044514A1/es unknown
- 2004-04-14 TW TW093110410A patent/TW200510353A/zh unknown
- 2004-04-14 CL CL200400800A patent/CL2004000800A1/es unknown
- 2004-04-14 PA PA20048600201A patent/PA8600201A1/es unknown
- 2004-04-14 NL NL1025946A patent/NL1025946C2/nl not_active IP Right Cessation
-
2005
- 2005-09-15 IS IS8033A patent/IS8033A/is unknown
- 2005-10-14 MA MA28552A patent/MA27764A1/fr unknown
- 2005-10-14 TN TNP2005000262A patent/TNSN05262A1/fr unknown
- 2005-10-14 ZA ZA200508362A patent/ZA200508362B/en unknown
- 2005-10-14 EC EC2005006105A patent/ECSP056105A/es unknown
- 2005-11-14 NO NO20055370A patent/NO20055370L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2521915A1 (en) | 2004-10-28 |
| CL2004000800A1 (es) | 2005-03-04 |
| UY28266A1 (es) | 2004-11-30 |
| ECSP056105A (es) | 2006-03-01 |
| AU2004230316A1 (en) | 2004-10-28 |
| NO20055370L (no) | 2006-01-12 |
| MXPA05010967A (es) | 2005-11-28 |
| CN1805943A (zh) | 2006-07-19 |
| MA27764A1 (fr) | 2006-02-01 |
| EP1615899A1 (en) | 2006-01-18 |
| OA13157A (en) | 2006-12-13 |
| EA200501462A1 (ru) | 2006-04-28 |
| TNSN05262A1 (fr) | 2007-07-10 |
| IS8033A (is) | 2005-09-15 |
| TW200510353A (en) | 2005-03-16 |
| PE20050415A1 (es) | 2005-06-13 |
| ZA200508362B (en) | 2006-11-29 |
| JP2006523671A (ja) | 2006-10-19 |
| WO2004092145A1 (en) | 2004-10-28 |
| NL1025946C2 (nl) | 2005-02-01 |
| AP2005003418A0 (en) | 2005-12-31 |
| PA8600201A1 (es) | 2005-02-04 |
| NL1025946A1 (nl) | 2004-10-18 |
| NO20055370D0 (no) | 2005-11-14 |
| WO2004092145A8 (en) | 2005-05-12 |
| BRPI0409429A (pt) | 2006-04-18 |
| AR044514A1 (es) | 2005-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20060009846A (ko) | Ｐｐａｒ 조절자로서의 알파 치환된 카복실산 | |
| US20050187266A1 (en) | Alpha substituted carboxylic acids | |
| US10946018B2 (en) | Spirocyclic compounds as tryptophan hydroxylase inhibitors | |
| US9573936B2 (en) | Triazole agonists of the APJ receptor | |
| US10131648B2 (en) | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | |
| US8119624B2 (en) | Fused phenyl amido heterocyclic compounds | |
| US11020395B2 (en) | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor | |
| US20050234066A1 (en) | Alpha substituted carboxylic acids | |
| JP2015506349A (ja) | 非全身性ｔｇｒ５アゴニスト | |
| US20150266822A1 (en) | Amide Compounds, Compositions And Uses Thereof | |
| JP2017524005A (ja) | オレキシンレセプターモジュレーターとしてのジフルオロピロリジン | |
| US20130261108A1 (en) | Compositions and methods for modulating farnesoid x receptors | |
| CN114478497A (zh) | 芳基烷基酸类glp-1受体激动剂及其用途 | |
| US10195178B2 (en) | GPR40 agonists in anti-diabetic drug combinations | |
| CN114269755A (zh) | 作为magl抑制剂的4,4a,5,7,8,8a-六吡啶并[4,3-b][1,4]噁嗪-3-酮化合物 | |
| TW201305146A (zh) | 經環胺取代之□唑啶酮ｃｅｔｐ抑制劑 | |
| US20220388997A1 (en) | Compounds for modulating activity of fxr and uses thereof | |
| TW202045498A (zh) | 作為法尼醇x受體調節劑之經取代雙環化合物 | |
| WO2012044567A2 (en) | Imidazole derivatives | |
| DE60128239T2 (de) | Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten | |
| KR20120011357A (ko) | 치환된 피리디논 유도체 및 이의 제조방법 | |
| TW200424201A (en) | Fused heteroaryl carboxylic acids as PPAR agonists | |
| JP2013147443A (ja) | β置換カルボン酸誘導体 | |
| EA046637B1 (ru) | Соединения для модуляции активности fxr и их применение | |
| KR20130015727A (ko) | 치환된 아제티딘 유도체 및 이를 포함하는 약학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |